FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950242558> ?p ?o ?g. }

• W2950242558 endingPage "406" @default.
• W2950242558 startingPage "405" @default.
• W2950242558 abstract "Background: Autoimmune haemolytic anaemia (AIHA) is characterized by haemolysis mediated by autoantibodies directed against red blood cells (RBCs). Warm antibody (wAIHA; 60%>70%) and cold agglutinin disease (CAD; 20%>25%) subclasses are defined by the immunoglobulin (Ig) isotype involved and its thermal optimum for binding RBCs. wAIHA is mediated by IgG while 90% of CAD is mediated by IgM isotypes. CAD and wAIHA outcomes can be life-threatening, but no therapies are approved. Complement C3b deposition on RBCs plays a central role in AIHA, accelerating phagocytosis in the liver and/or spleen (extravascular haemolysis) and forming membrane attack complexes (intravascular haemolysis). By blocking formation of C3b, APL-2, a cyclic peptide, has potential as a novel therapeutic for AIHA. Aims: To assess whether inhibiting complement C3 with daily subcutaneous (SC) doses of APL-2 (270 mg/day or 360 mg/day) prevents intra- and extravascular haemolysis in AIHA subjects, reducing anaemia associated signs and symptoms. Methods: Subjects with primary AIHA were eligible for this Ph 2 open-label study to assess the safety, tolerability, efficacy, and pharmacokinetics of APL-2. Subjects had haemoglobin (Hb) levels < 11 g/dL, signs of haemolysis, and a positive direct agglutinin test (DAT) for IgG and/or complement C3. Twenty-four subjects (13 CAD, 11 wAIHA) were recruited and will be treated with APL-2 for 48 weeks. Efficacy was assessed by change from baseline in Hb, transfusion requirements, absolute reticulocyte counts (ARC), lactate dehydrogenase (LDH), haptoglobin, indirect bilirubin (INDBIL), and Functional Assessment of Illness Therapy (FACIT) fatigue score. Data are reported after 16 weeks (Day 112). Results: Two of 13 CAD subjects withdrew; 7 of 11 remaining subjects reached Day 112. Mean Hb (standard error [SE]) increased from 8.9 (0.4) [n = 13] to 11.6 (0.5) [n = 7] g/dL, and mean LDH, ARC, and INDBIL returned within normal range. Mean FACIT scores (SE) increased 9.9 (3.4) points from baseline. Two subjects had pre-study and 1 had on-study transfusions (normalized to 112 days). All 13 CAD experienced ≥1 treatment-emergent adverse event (TEAE), mainly Grade 1–2 and unrelated. Four subjects reported 10 unrelated serious adverse events (SAEs) (6 SAEs in 1 subject). Three subjects experienced 3 unrelated Grade 3 TEAEs (pneumonia, dyspnoea, hypertension); 1 subject reported 2 unrelated Grade 4 TEAEs (high calcium, high creatinine) and withdrew. Eight of 11 wAIHA subjects were DATmonoC3+ and 3 were DATmonoC3-. Two of 3 DATmonoC3- withdrew for lack of response and efficacy data are reported for 8 DATmonoC3+ subjects. Six of these reached Day 112. Mean Hb (SE) increased from 9.2 (0.3) [n = 8] to 10.8 (0.5) [n = 6] g/dL, and mean ARC and INDBIL returned within normal. Mean FACIT scores (SE) increased 2.7 (2.8) points from baseline. One subject had pre-study and 2 had on-study transfusions (normalized to 112 days). Ten of 11 wAIHA (C3+ and C3-) experienced ≥1 TEAE, mainly Grade 1–2 and unrelated. Five subjects reported 8 unrelated SAEs. Five subjects experienced 13 unrelated Grade 3 TEAEs (oral squamous cell carcinoma, haemolytic flare, purpura, acute kidney injury, dyspnoea, chest pain); 1 subject reported 1 unrelated Grade 4 TEAE (haemolytic flare) and withdrew. Six-month data for 10 CAD and 6 wAIHA C3+ is planned for June 2019. Summary/Conclusion: APL-2 increases Hb values in CAD and wAIHA C3+ within the first weeks of treatment with sustained benefit with longer exposure. APL-2 reduces intra- and extravascular haemolysis shown by reductions in LDH, INDBIL, and ARC. APL-2 appears to be safe and well-tolerated." @default.
• W2950242558 created "2019-06-27" @default.
• W2950242558 creator A5000352726 @default.
• W2950242558 creator A5023401677 @default.
• W2950242558 creator A5027094790 @default.
• W2950242558 creator A5032982255 @default.
• W2950242558 creator A5034535532 @default.
• W2950242558 creator A5044175321 @default.
• W2950242558 creator A5059381857 @default.
• W2950242558 creator A5061128028 @default.
• W2950242558 creator A5061348179 @default.
• W2950242558 creator A5076368199 @default.
• W2950242558 date "2019-06-01" @default.
• W2950242558 modified "2023-10-11" @default.
• W2950242558 title "S900 EVIDENCE BASED USE OF ERYTRHOPOIETIN IN PATIENTS WITH AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER INTERNATIONAL STUDY" @default.
• W2950242558 doi "https://doi.org/10.1097/01.hs9.0000561880.96057.ca" @default.
• W2950242558 hasPublicationYear "2019" @default.
• W2950242558 type Work @default.
• W2950242558 sameAs 2950242558 @default.
• W2950242558 citedByCount "0" @default.
• W2950242558 crossrefType "journal-article" @default.
• W2950242558 hasAuthorship W2950242558A5000352726 @default.
• W2950242558 hasAuthorship W2950242558A5023401677 @default.
• W2950242558 hasAuthorship W2950242558A5027094790 @default.
• W2950242558 hasAuthorship W2950242558A5032982255 @default.
• W2950242558 hasAuthorship W2950242558A5034535532 @default.
• W2950242558 hasAuthorship W2950242558A5044175321 @default.
• W2950242558 hasAuthorship W2950242558A5059381857 @default.
• W2950242558 hasAuthorship W2950242558A5061128028 @default.
• W2950242558 hasAuthorship W2950242558A5061348179 @default.
• W2950242558 hasAuthorship W2950242558A5076368199 @default.
• W2950242558 hasBestOaLocation W29502425581 @default.
• W2950242558 hasConcept C126322002 @default.
• W2950242558 hasConcept C203014093 @default.
• W2950242558 hasConcept C2776175824 @default.
• W2950242558 hasConcept C2777385706 @default.
• W2950242558 hasConcept C2778248108 @default.
• W2950242558 hasConcept C71924100 @default.
• W2950242558 hasConceptScore W2950242558C126322002 @default.
• W2950242558 hasConceptScore W2950242558C203014093 @default.
• W2950242558 hasConceptScore W2950242558C2776175824 @default.
• W2950242558 hasConceptScore W2950242558C2777385706 @default.
• W2950242558 hasConceptScore W2950242558C2778248108 @default.
• W2950242558 hasConceptScore W2950242558C71924100 @default.
• W2950242558 hasIssue "S1" @default.
• W2950242558 hasLocation W29502425581 @default.
• W2950242558 hasLocation W29502425582 @default.
• W2950242558 hasOpenAccess W2950242558 @default.
• W2950242558 hasPrimaryLocation W29502425581 @default.
• W2950242558 hasRelatedWork W2013954738 @default.
• W2950242558 hasRelatedWork W2057890429 @default.
• W2950242558 hasRelatedWork W2119226703 @default.
• W2950242558 hasRelatedWork W2396594311 @default.
• W2950242558 hasRelatedWork W2409171937 @default.
• W2950242558 hasRelatedWork W2412076877 @default.
• W2950242558 hasRelatedWork W2412379808 @default.
• W2950242558 hasRelatedWork W2415699880 @default.
• W2950242558 hasRelatedWork W2415873380 @default.
• W2950242558 hasRelatedWork W2417870495 @default.
• W2950242558 hasRelatedWork W2419065474 @default.
• W2950242558 hasRelatedWork W2426759677 @default.
• W2950242558 hasRelatedWork W2432071818 @default.
• W2950242558 hasRelatedWork W2441267222 @default.
• W2950242558 hasRelatedWork W2596296510 @default.
• W2950242558 hasRelatedWork W2770265331 @default.
• W2950242558 hasRelatedWork W2884071658 @default.
• W2950242558 hasRelatedWork W2970161928 @default.
• W2950242558 hasRelatedWork W3111585970 @default.
• W2950242558 hasRelatedWork W2775191434 @default.
• W2950242558 hasVolume "3" @default.
• W2950242558 isParatext "false" @default.
• W2950242558 isRetracted "false" @default.
• W2950242558 magId "2950242558" @default.
• W2950242558 workType "article" @default.